Gyre Therapeutics, Inc. (GYRE)
6.16
+0.11
(+1.82%)
USD |
NASDAQ |
Jun 09, 14:49
Gyre Therapeutics SG&A Expense (Quarterly) : 21.36M for March 31, 2026
SG&A Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
SG&A Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (Quarterly) Benchmarks
| Marker Therapeutics, Inc. | 1.230M |
| Savara, Inc. | 15.57M |
| Vericel Corp. | 49.23M |
| Krystal Biotech, Inc. | 41.01M |
| ACADIA Pharmaceuticals, Inc. | 171.02M |